Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
About Choroidal Neovascularization
Choroidal neovascularization is the formation of new blood vessels in the choroid layer of the eye. These vessels grow through the Bruch membrane into the subretinal space, blocking the proper functioning of retina and leading to vision loss. The condition is often associated with myopia, malignant myopic degeneration, or age-related macular degeneration (AMD).
Technavio’s analysts forecast the global choroidal neovascularization market to grow at a CAGR of 6.64% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global choroidal neovascularization market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of choroidal neovascularization.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Choroidal Neovascularization Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bayer HealthCare
• Novartis
• Regeneron Pharmaceuticals
• F. Hoffmann-La Roche
Other prominent vendors
• Alcon
• Allergan
• Avalanche
• Bausch and Lomb
• Gilead Sciences
• Iconic Therapeutics
• Lpath
• Neurotech Pharmaceuticals
• Ohr Pharmaceutical
• Opthea
• Ophthotech
• PanOptica
• Pfizer
• Promedior
• QLT
• Quark
• Resolvyx Pharmaceuticals
• RXi Pharmaceuticals
• Sagent Pharmaceuticals
• Santen
• Sanwa Kagaku Kenkyusho
Market driver
• Growing older population
• For a full, detailed list, view our report
Market challenge
• High cost of treatment
• For a full, detailed list, view our report
Market trend
• Strategic alliances and M&A
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Choroidal neovascularization is the formation of new blood vessels in the choroid layer of the eye. These vessels grow through the Bruch membrane into the subretinal space, blocking the proper functioning of retina and leading to vision loss. The condition is often associated with myopia, malignant myopic degeneration, or age-related macular degeneration (AMD).
Technavio’s analysts forecast the global choroidal neovascularization market to grow at a CAGR of 6.64% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global choroidal neovascularization market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of choroidal neovascularization.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Choroidal Neovascularization Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bayer HealthCare
• Novartis
• Regeneron Pharmaceuticals
• F. Hoffmann-La Roche
Other prominent vendors
• Alcon
• Allergan
• Avalanche
• Bausch and Lomb
• Gilead Sciences
• Iconic Therapeutics
• Lpath
• Neurotech Pharmaceuticals
• Ohr Pharmaceutical
• Opthea
• Ophthotech
• PanOptica
• Pfizer
• Promedior
• QLT
• Quark
• Resolvyx Pharmaceuticals
• RXi Pharmaceuticals
• Sagent Pharmaceuticals
• Santen
• Sanwa Kagaku Kenkyusho
Market driver
• Growing older population
• For a full, detailed list, view our report
Market challenge
• High cost of treatment
• For a full, detailed list, view our report
Market trend
• Strategic alliances and M&A
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
